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Abstract
Background: Multi-morbidity and polypharmacy increase the risk of non-trivial adverse drug reactions (ADRs) in older
people during hospitalization. Despite this, there are no established interventions for hospital-acquired ADR prevention.
Methods: We undertook a pragmatic, multi-national, parallel arm prospective randomized open-label, blinded endpoint
(PROBE) controlled trial enrolling patients at six European medical centres. We randomized 1,537 older medical and
surgical patients with multi-morbidity and polypharmacy on admission in a 1:1 ratio to SENATOR software-guided
medication optimization plus standard care (intervention, n= 772, mean number of daily medications= 9.34) or standard
care alone (control, n= 765, mean number of daily medications= 9.23) using block randomization stratified by site and
admission type. Attending clinicians in the intervention arm received SENATOR-generated advice at a single time point
with recommendations they could choose to adopt or not. The primary endpoint was occurrence of probable or certain
ADRs within 14 days of randomization. Secondary endpoints were primary endpoint derivatives; tertiary endpoints included
all-cause mortality, re-hospitalization, composite healthcare utilization and health-related quality of life.
Results: For the primary endpoint, there was no difference between the intervention and control groups (24.5 vs. 24.8%; OR
0.98; 95% CI 0.77–1.24; P = 0.88). Similarly, with secondary and tertiary endpoints, there were no significant differences.
Among attending clinicians in the intervention group, implementation of SENATOR software-generated medication advice
points was poor (∼15%).
Conclusions: In this trial, uptake of software-generated medication advice to minimize ADRs was poor and did not reduce
ADR incidence during index hospitalization.
Keywords:adverse drug reactions, older people,multi-morbidity, polypharmacy, prevention, STOPP/START criteria, software
Key Points
• Previous single-centre randomized clinical trials (RCTs) have shown that application and implementation of STOPP/S-
TART rules for avoidance of PIP errors significantly reduced ADR incidence in hospitalized older people.
• SENATOR is the first large-scale, multi-centre RCT assessing the effect of a software engine for electronic deployment of
STOPP/START prescribing rules on incident ADRs in older people living with multi-morbidity hospitalized with acute
illness under the care of specialists other than geriatricians.
• Compared with patients allocated to the control arm, i.e. usual pharmaceutical care, incident ADRs in patients assigned to
the SENATOR software intervention arm of the SENATOR trial were comparably frequent, i.e. 24.5 versus 24.8%.
• Although SENATOR software successfully and accurately deployed STOPP/START criteria alongsidemajor drug–drug and
drug–disease interaction alerts, implementation of SENATOR prescribing advice points by attending physician prescribers
is poor, i.e. ∼15%.
• For electronic prescribing advice to be effective for prevention of ADRs in hospitalized multi-morbid older patients, a
further element is required over and above provision of prescribing advice reports, most likely face-to-face interaction with
expert physicians or pharmacists.
Introduction
Research consistently shows that adverse drug reactions
(ADRs) in older people relate directly to polypharmacy
[1], which is causally linked to multi-morbidity [2]. ADRs
cause substantial morbidity and mortality among older
patients in hospital [3]. In a recent US study of emergency
department (ED) visits, the highest rates of ADR-related
ED attendance and subsequent hospitalization across all age
groups occurred in older people [4]. In relation to patient
safety, ADRs in older people during hospitalization are
particularly concerning. A systematic review by Alhawassi
et al . [5] concluded that at least 10% of older patients
experience ADRs that lead to hospitalization or occur during
acute hospitalization itself. Female sex, multi-morbidity
and polypharmacy were the main risk factors for ADRs
in this population. ADRs have serious adverse effects on
the health, functional status and quality of life of older
people [6, 7] and increase healthcare costs [8, 9]. In its third
Global Patient Safety Challenge in 2017, the World Health
Organization in recognizing the threat from ADRs to patient
safety committed to finding ways to reduce serious avoidable
harm related to medications by 50% over 5 years [10].
Experts generally agree that inappropriate prescribing in
older people predisposes to ADRs [11–14]. Therefore, one
strategy for preventing ADRs is to screen older patients’
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medications using criteria for potentially inappropriate pre-
scribing (PIP) such as Beers criteria [15] or STOPP criteria
[16]. To date, there are four published single-centre prospec-
tive randomized controlled trials in which application of
STOPP criteria as an intervention has been compared with
standard pharmaceutical care [17–20].These trials show that
routinely applying STOPP criteria significantly reduces PIP,
ADR incidence, falls and medication costs in hospitalized
older multi-morbid patients. However, each of these studies
was single-centre, not double-blinded and STOPP criteria
were not automated.
Most prescribing for older people living with multi-
morbidity with polypharmacy is done by physicians
who are not specialized in geriatric medicine or clinical
pharmacology. Since age-related multi-morbidity causes
polypharmacy and polypharmacy heightens PIP and
ADR risk [21], routine screening for PIP among older
people attended by non-specialist physicians is one logical
approach to reducing ADRs. Furthermore, most de-
prescribing in hospital is reactive, not proactive, indicating
that prescribing prompts to attending physicians may be
required [22].
In recent years, systematic reviews have examined the
medication optimizing impact of clinical decision support
systems (CDSS) in older people living with multi-morbidity
in various clinical settings [23–26]. Although conclusions
vary, CDSS have, in general, been found to reduce PIP [27].
No clinical trial, however, has examined whether CDSS-
deployed PIP criteria in the acute hospital setting reduce
ADRs in acutely ill multi-morbid older patients.
Therefore, the central aim of this multi-centre trial was to
determine whether providing CDSS-generated medication
advice reports based predominantly on PIP criteria to clin-
icians attending hospitalized acutely ill older people living
with multi-morbidity significantly reduces ADR incidence.
Patients and methods
We designed a pragmatic prospective randomized open-
label, blinded endpoint (PROBE) controlled trial involving
six European medical centres (Ireland, Scotland, Spain, Italy,
Belgium and Iceland). We screened patients hospitalized
with acute unselected medical and surgical illness for trial
enrolment. All six centres were large academic teaching
hospitals that routinely received unselected acute medical
cases for admission across a range of clinical specialties.
Each centre has a long-established geriatric medicine ser-
vice providing specialist care and advice on management of
patients aged ≥65 years admitted under the care of specialist
departments other than geriatric medicine. The focus of the
SENATOR trial is the need to optimize the appropriateness
of older patients’ prescriptions to avoid ADRs. The central
hypothesis in the SENATOR trial is that attending medical
staff prescribers working in specialist departments other than
geriatric medicine will—when offered advice points relat-
ing to potentially inappropriate medication in individual
patients under their care—adjust the prescriptions of these
patients according to the SENATOR software-generated
advice reports (the intervention). These adjustments will,
in turn, significantly reduce ADR incidence in intervention
arm patients compared to matched patients receiving stan-
dard pharmaceutical care in the samemedical centre. Further
details are provided in a previous trial protocol paper [34]
and are summarized in Supplementary data file.
Results
Figure 1 shows the CONSORT flow diagram for the trial.
From July 2016 to February 2018, we screened 17,657
patients and randomized 1,537 patients to intervention
(n= 772) or control (n= 765) groups (see screening failure
details in Supplementary data file). Patient recruitment
was distributed as follows: Cork 405 patients (26.4%),
Reykjavik 295 patients (19.2%), Aberdeen 285 patients
(18.5%), Ghent 205 patients (13.3%), Madrid 190 patients
(12.4%) and Ancona 157 patients (10.2%). The median
(IQR) length of stay (LOS) in the control patients was
6 days [3–12], in the intervention patients it was also 6
days [3–10] (Table 1). Baseline control and intervention
groups were well matched at baseline (Table 2), with no
significant differences noted for age, sex, number of daily
prescription drugs, CIRS-G score, MMSE score, BI score
or level of dependency (requirement for daily personal and
domestic help). We randomized patients from 21 specialties,
i.e. 13medical and eight surgical clusters (see Supplementary
data file), with similar proportions of patients from medical
and surgical clusters in the control and intervention
populations.
Eight hundred and twenty-eight trigger list adverse events
(Table 1) occurred in the 1,537 randomized patients; by
Hartwig and Siegel criteria, 215 (26.0%) events were mild,
564 (68.1%) moderate, 41 (4.9%) severe and 8 (1%)
fatal. There were 475 confirmed primary endpoints in 379
patients, i.e. 24.7%; 84 ADRs were mild (17.7%), 364
moderate (76.6%), 24 severe (5.1%) and 3 fatal (0.6%).The
primary endpoint occurred in 190 control patients (24.8%)
compared to 189 intervention patients (24.5%; OR 0.98;
95% CI 0.77–1.24; P = 0.88). Results were similar for all
secondary endpoints (Table 3), and post-hoc adjustment for
additional covariates did not significantly affect the results.
Adherence among attending clinicians with the SENA-
TOR software-generated medication recommendations was
substantially lower than expected, i.e. 15.0% on average
across the six participating sites (Figure 2). The pattern of
adherence with STOPP recommendations that constituted
the majority of SENATOR report recommendations was
also lower than expected across the six clinical sites (average
19.7%, see Supplementary data file).
As with the primary and secondary ADR-related
endpoints, no significant differences were detected between
control and intervention groups for any tertiary endpoints
(Table 3; Supplementary data file).
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Figure 1. CONSORT flow diagram for the SENATOR trial. All analyses were based on the intention-to-treat principle.
Discussion
SENATOR is the first large-scale multi-national clinical
trial examining the impact of a customized CDSS medica-
tion optimization intervention on incident ADRs in acutely
ill older people in hospital. The trial has yielded negative
results probably because intervention arm clinicians did
not implement SENATOR software-generated medication
recommendations at a sufficiently high frequency.
SENATOR was a pragmatic trial to test the impact of the
CDSS-generated reports delivered to attending physicians
on incident ADRs without other influences within the inter-
vention.We designed the SENATOR trial protocol such that
attending clinicians retained full control of their patients’
drug prescriptions; i.e. they could accept or reject SENA-
TOR recommendations using their own clinical judgment
in each case. The trial design followed the hypothesis that
attending clinicians when presented with CDSS-generated
evidence-based prescribing advice will, in general, apply
that advice when it is deemed appropriate in individual
cases. A previous single-centre trial had shown high-level
adherence with STOPP/START recommendations gener-
ated without CDSS support [20]. In that trial, a trained
physician provided STOPP/START recommendations at a
time when a sufficiently efficient and reliable software vehicle
for application of STOPP/START criteria was not available.
The trained physician applied STOPP/START criteria to the
medications of intervention arm patients within 48 hours
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Table 1. Pre-specified ‘trigger list’ of adverse events, which formed the basis of ADR identification and corroboration. All
trigger list events were notified to members of the blinded endpoint committee such that blinded adjudicators did not assess
potential ADRs occurring in their own site.
Pre-specified event Definition
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fall/s New onset of one or more falls.
New onset unsteady gait New onset of unsteady gait that results in poor mobility and unsteady balance.
Acute kidney injury An increase in serum creatinine by 0.3 mg/dl (26.5 μmol/L) within 48 hours or
an increase in serum creatinine by 1.5 baseline, which is known or presumed to
have occurred within the prior 7 days.
Symptomatic orthostatic hypotension A systolic blood pressure drop ≥20 mmHg ± diastolic blood pressure drop
≥10 mmHg within 3 minutes of standing from the lying or sitting posture
associated with symptoms.
Major serum electrolyte disturbance Serum sodium <130 or> 145 mmol/L and/or
Serum potassium <3.5 or >5.2 mmol/L and/or
Corrected serum calcium <2.1 or >2.7 mmol/L.
Symptomatic bradycardia Heart rate of <50 beats/minute with symptoms.
New-onset major constipation Subjective symptoms of hard stools and/or <3 bowel movements per week
and/or supported by nursing records.
Acute bleeding Melena or haematuria or haematemesis or haemoptysis with or without a drop in
haemoglobin level>2 g/dL (not due to rehydration) or associated symptoms
(hypotension, tachycardia, pallor) or secondary renal failure.
Acute dyspepsia/nausea/vomiting Subjective symptoms of acute ‘indigestion’/’upset stomach’ or acute abdominal
pain or acute refusal to eat or acute heartburn/acid reflux or acute
nausea/vomiting.
Acute diarrhoea New onset liquid stools reported by the patient or the nursing staff or new liquid
stools detected by medical staff on physical examination or new liquid
(non-solid) stools occurring more than 3 times in 24 hours.
Acute delirium Confirmed by a reliable witness and meeting DSM-Va criteria. Supported by a
4ATb ≥ 4 and/or MMSEc <23/30.
Symptomatic hypoglycaemia Symptoms with a blood glucose of <63 mg/dL or 3.5 mmol/L.
Unspecified adverse event Deleterious events not specified above, e.g. acute liver failure, anaphylaxis.
aDSM-V: diagnostic and Statistical Manual of mental disorders, 5th edition. b4AT: the 4AT screening instrument for cognitive impairment and delirium. cMMSE:
mini-Mental State Examination.
Figure 2. Uptake of SENATOR software medication advice points in each of the six participating centres. On average, 15% of
the software-generated advice points presented in the form of a software-generated medication advice report were implemented by
attending physicians in the intervention arm.
of admission and provided the details of the contravened
STOPP/START criteria in person to the attending senior
residents or consultants, supplemented by an individualized
printed report. Although delivery of STOPP/START criteria
advice by a trained physician is highly effective for ADR
prevention, it is however unlikely to be cost effective [35].
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Table 2. Details of baseline characteristics in randomized patients in the SENATOR trial
Variable N Total (n= 1,537) Control (n= 765) Intervention (n= 772)
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Clinical site 6
Site 1,537
Cork (Ireland) 405 (26.4%) 201 (26.3%) 204 (26.4%)
Reykjavik (Iceland) 295 (19.2%) 147 (19.2%) 148 (19.2%)
Aberdeen (Scotland) 285 (18.5%) 141 (18.4%) 144 (18.7%)
Madrid (Spain) 190 (12.4%) 95 (12.4%) 95 (12.3%)
Ghent (Belgium) 205 (13.3%) 102 (13.3%) 103 (13.3%)
Ancona (Italy) 157 (10.2%) 79 (10.3%) 78 (10.1%)
Sex 1,537
Female 725 (47.2%) 358 (46.8%) 367 (47.5%)
Age (years, IQR) 1,537 78 [72, 84] 78 [72, 84] 78 [72, 84]
Education 1,537
No schooling 37 (2.4%) 16 (2.1%) 21 (2.7%)
Primary school education only 561 (36.5%) 283 (37%) 278 (36%)
Some secondary education 281 (18.3%) 146 (19.1%) 135 (17.5%)
Complete secondary education 448 (29.1%) 203 (26.5%) 245 (31.7%)
Some third-level education 55 (3.6%) 25 (3.3%) 30 (3.9%)
Complete third-level education 155 (10.1%) 92 (12%) 63 (8.2%)
Smoker 1,537
Yes 108 (7%) 52 (6.8%) 56 (7.3%)
No 1,429 (93%) 713 (93.2%) 716 (92.7%)
Alcohol 1,537
Yes 432 (28.1%) 209 (27.3%) 223 (28.9%)
No 1,105 (71.9%) 556 (72.7%) 549 (71.1%)
Domestic assistance required 1,515a 604 (39.9%) 302 (39.9%) 302 (39.8%)
Personal care required 1,515a 384 (25.3%) 191 (25.2%) 193 (25.5%)
CIRS-G score 1,537 15 [11, 19] 15 [11, 19] 15 [11, 19]
Fall(s) in the previous 12 months 1,537 570 (37.1%) 290 (37.9%) 280 (36.3%)
Previous documented ADR(s) 1,537 669 (43.5%) 327 (42.7%) 342 (44.3%)
Barthel Index (median [IQR]) 1,537 18 [14, 20] 18 [14, 20] 18 [14, 20]
Mini-Mental State Examination
(median [IQR])
1,503a 27 [23, 29] 27 [24, 29] 27 [23, 29]
Number of daily medications (median
[IQR])
1,537 10 [8, 13] 10 [8, 13] 10 [8, 13]
IQR, inter-quartile range. aData available in <100% of patients.
The SENATOR trial aimed to match the performance of
the earlier single-centre trial but in a multi-centre context
using software-generated advice reports only (as distinct
from physician-delivered and moderated reports), i.e. an
intervention that would likely be cost effective.
There are several possible reasons for poor prescribing
advice adherence among attending clinicians observed at
all six sites in the SENATOR trial. A follow-up qualitative
study towards the end of trial patient recruitment using the
Theoretical Domains Framework methodology [36] applied
to transcribed audio-recorded interviews with 10 primary
researchers and 14 physician prescribers from the six sites
identified four predominant factors that influence SENA-
TOR software advice adherence [37]. These included (i)
the computerized advice reports frequently producing rec-
ommendations of low clinical relevance in the context of
serious acute illness, contributing to prescriber ‘alert fatigue’;
(ii) the frequently busy pressurized acute hospital environ-
ment having a negative impact on timing and location of
medication advice delivery; (iii) prescribers’ variable level
of experience/responsibility and attitude to clinical trials;
(iv) patient-specific issues including clinicians’ knowledge
of patients’ diagnostic details, medication preferences and
clinical status in hospital. Other possible reasons for poor
SENATORCDSS advice implementation include belief that
long-term prescribing adjustment is essentially the respon-
sibility of patients’ primary care physicians, reluctance to
adjust medications outside of one’s own expertise and lack
of awareness about highly prevalent ADRs and the high
risk of incident ADRs in multi-morbid older patients. Some
SENATOR advice points may have been technically correct
but not appropriate for application in certain patients during
their acute illness. For example, STOPP criterion K1 that
recommends avoidance of benzodiazepines in those at risk
of falls may not be easy or appropriate to implement in
some older patients in the context of acute illness in the
hospital setting because of heightened risk of benzodiazepine
withdrawal syndrome and exacerbation of clinical status.
Another theoretical reason for poor SENATOR advice
implementation is very short hospital LOS. All patients
were randomized to control or intervention groups within
60 hours (the great majority within 24 hours) of admis-
sion, and primary and secondary endpoints were assessed at
discharge or day 14 whichever came first and the median
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Table 3. The distributions for each endpoint, as well as model estimated effects of the SENATOR intervention. Endpoint
distributions are described by their counts and percentages in each category (primary; S1, S2; tertiary, i.e. mortality and
re-hospitalization), and by their median, IQR and total range (SPC, S1C, S2C). Model results comparing SENATOR
(intervention) and control groups are from logistic regression for the primary endpoint, the S1 and S2 secondary endpoints,
and mortality and re-hospitalization as tertiary endpoints; from Poisson regression for the SPC, S1C and S2 secondary
endpoints. Estimates are adjusted for clinical centre and medical versus surgical admission. EQ5D-3 L tertiary endpoint
results are presented in Table 3a of the Supplementary data file
Endpoint N Combined control and
SENATOR (n= 1,537)
Control (n= 765) SENATOR (n= 772) Model results estimate
(95% confidence
interval); P-value
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Primary 1,537 379 (24.7%) 190 (24.8%) 189 (24.5%) OR= 0.98
(0.77–1.24); 0.88
S1 1,537 541 (35.2%) 281 (36.7%) 260 (33.7%) OR= 0.87
(0.70–1.08); 0.20
S2 1,537 339 (22.1%) 175 (22.9%) 164 (21.2%) OR= 0.91
(0.71–1.15); 0.42
SPC 1,537 0 [0, 0] (0–4) 0 [0, 0] (0–4) 0 [0, 0] (0–4) RR= 0.93
(0.78–1.11); 0.42
S1C 1,537 0 [0, 1] (0–6) 0 [0, 1] (0–5) 0 [0, 1] (0–6) RR= 0.88
(0.77–1.01); 0.08
S2C 1,537 0 [0, 0] (0–4) 0 [0, 0] (0–4) 0 [0, 0] (0–3) RR= 0.90
(0.74–1.09); 0.30
Mortality (all-cause)
within 30 days of
randomization
1,449 105 (7.2%) 51 (7.1%) 54 (7.2%) OR= 1.05
(0.70–1.57); 0.81
Re-hospitalization
(all-cause) at 12 weeks
of discharge
1,332 474 (35.6%) 231 (34.9%) 243 (36.2%) OR= 1.05
(0.84–1.32); 0.66
OR, odds ratio; RR, relative risk; DM, difference in means; CI, confidence interval. Key to secondary endpoints: S1: ≥1 adjudicated possible, probable or certain,
non-trivial, hospital-acquired ADRs occurring within 14 days of randomization during the index hospitalization. S2:≥1 adjudicated probable or certain, non-trivial,
hospital-acquired, pre-specified ADRs occurring within 14 days of randomization during the index hospitalization. SPC: total number of adjudicated probable
or certain, non-trivial hospital-acquired ADRs occurring within 14 days of randomization during the index hospitalization. S1C: total number of adjudicated
possible, probable or certain, non-trivial, hospital-acquired ADRs occurring within 14 days of randomization during the index hospitalization. S2C: total number
of adjudicated probable or certain, non-trivial, hospital-acquired, pre-specified ADRs occurring within 14 days of randomization during the index hospitalization.
LOS in both control and intervention groups was 6 days.
Thus, whilst relatively short admissions could explain the
lack of implementation of SENATOR advice points in some
cases, it is unlikely that this was the main reason in most
intervention patients.
Because SENATOR advice implementation was poor in
all centres, we contend that for future medication optimiza-
tion interventions in older multi-morbid patients to succeed,
ensuring medication optimization advice implementation
among attending clinicians will be crucial. In previous stud-
ies, face-to-face verbal interaction with attending clinicians
by trained physicians or pharmacists helped to enhance
medication advice adherence [20, 32] and should therefore
become an integral feature of any future CDSS intervention
trial design involving older patients with chronic multi-
morbidity and polypharmacy.
Previous research shows that routine medication advice
presented by appropriately trained pharmacists reduces
inappropriate prescribing in multi-morbid older patients
[38], although not to the same extent as physician-
delivered advice. Notably, however, the high level of
prescriber acceptance of pharmacist-delivered medication
recommendations in these studies occurred in the context
of specialized pharmacists working closely with geriatricians
in an integrated specialist team using structured medication
review [38]. The challenge for the future is how to reproduce
the efficacy of such a system across the wide range of
specialist departments within most large hospitals. Recent
work by Quintens et al . [40] shows that routine medication
appropriateness surveillance by a trained pharmacist in
addition to electronic medication alerts based on an
integrated computerized physician order entry system
supported by a CDSS achieved 83% medication advice
implementation. Electronic prompts to attending physicians
alone achieved 56% adherence in the tertiary referral
centre involved in that study where medical records and
prescriptions were fully electronic. Interestingly, comparable
STOPP and START criteria adherence (81.2 and 87.4%,
respectively) was achieved by O’Connor et al . [20] when
STOPP/START medication advice was conveyed verbally
by a senior resident in geriatric medicine reinforced by a
printed advice report. Such qualified prescribing advice may
counteract some of the negative effects of adhering strictly to
disease-specific guidelines contributing to ‘evidence-biased’
overprescribing in older multi-morbid patients [39, 41].
Using a novel ADR detection system, we recorded an
overall hospital-acquired ADR incidence of 24.7% in SEN-
ATOR trial patients, substantially higher than previously
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reported in the literature, i.e. 6.3–11.5% [42, 43]. Such a
high ADR incidence mandates routine screening for PIP
and intervention to attenuate PIP-related ADRs, thereby
maintaining patient safety from adverse medication. With-
out such structuredmedication surveillance by trained physi-
cians or pharmacists to promote better implementation of
medication advice, ADRs will continue to compromise older
patient safety.
There are some limitations to the present study. In the
original trial design, we had calculated that for the trial
to have 90% statistical power, 900 patients in either trial
arm; i.e. 1,800 patients would be needed for randomiza-
tion. Because of time and resource constraints, we random-
ized 1,537 patients, i.e. 85.4% of the target number. It
is unlikely, however, that SENATOR advice implementa-
tion would have been substantially different even if we had
randomized 1,800 patients. Another limitation is the lack
of cluster randomization with the theoretical advantage of
minimizing trial contamination. However, from the earlier
observational study [30] in which the eCRF was tested and
subsequently refined, we discovered substantial heterogene-
ity in ADR incidence between the clinical sites and within
particular specialties across the sites. In addition, the ADR
prediction tools available were not robust enough to correct
for between-cluster ADR variability in baseline ADR risk.
Thus, we could not exclude the possibility that any observed
differences in ADR incidence might result from unequal
distribution of ADR risk at baseline. For these reasons, we
decided on individual-level randomization rather than on
cluster randomization, accepting that cross-arm contamina-
tion could in theory diminish the intervention effect size.
The lack of a prior pilot evaluation of the intervention is
another limitation. However, with major time and resource
constraints, the SENATOR trial was already substantially
delayed by the time it began such that the imperative was
to proceed with the trial as per protocol. The delay with
starting the trial was mainly due to unforeseen delay with
completion and validation of the SENATOR software and
achieving successful interface with the eCRF. Finally, a full
assessment by an expert in implementation science would
have been ideal prior to starting the trial. However, once
again, constrained time and resources did not allow for this.
In a recent commentary, Shortliffe and Sepulveda [44]
emphasized that future studies evaluating any CDSS must
focus on how well a CDSS performs any clinical task com-
pared to the same task being performed by experts. They
also emphasized that any CDSS must be fail-safe, should
not harm patients and should integrate easily with existing
workflows. However, even with all these necessary attributes
of a reliable and safe system, any CDSS must be acceptable
to clinicians to be effective. In relation to medication opti-
mization in multi-morbid hospitalized older patients, the
SENATOR trial shows that a CDSS can be safe and efficient
but still lack impact if attending clinicians do not implement
the medication advice provided. Future trials should evaluate
interventions that incorporate efficient software delivery of
prescribing advice combined with direct face-to-face contact
between attending clinicians and trained physicians or phar-
macists who promote the principles of comprehensive geri-
atric assessment including pharmacotherapy optimization.
We contend that for CDSS-based medication optimization
interventions in multi-morbid older patients to succeed this
combination is essential.
Supplementary data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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